- Home
- SWVL vs VTVT Comparison
SWVL vs VTVT Comparison
Compare SWVL & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- VTVT
- Stock Information
- Founded
- SWVL 2017
- VTVT 2015
- Country
- SWVL United Arab Emirates
- VTVT United States
- Employees
- SWVL N/A
- VTVT N/A
- Industry
- SWVL Business Services
- VTVT Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- VTVT Health Care
- Exchange
- SWVL Nasdaq
- VTVT Nasdaq
- Market Cap
- SWVL 40.6M
- VTVT 41.9M
- IPO Year
- SWVL N/A
- VTVT 2015
- Fundamental
- Price
- SWVL $3.44
- VTVT $18.54
- Analyst Decision
- SWVL
- VTVT Strong Buy
- Analyst Count
- SWVL 0
- VTVT 2
- Target Price
- SWVL N/A
- VTVT $35.50
- AVG Volume (30 Days)
- SWVL 16.9K
- VTVT 2.5K
- Earning Date
- SWVL 04-02-2025
- VTVT 08-12-2025
- Dividend Yield
- SWVL N/A
- VTVT N/A
- EPS Growth
- SWVL N/A
- VTVT N/A
- EPS
- SWVL N/A
- VTVT N/A
- Revenue
- SWVL $17,207,362.00
- VTVT $17,000.00
- Revenue This Year
- SWVL N/A
- VTVT N/A
- Revenue Next Year
- SWVL N/A
- VTVT N/A
- P/E Ratio
- SWVL N/A
- VTVT N/A
- Revenue Growth
- SWVL N/A
- VTVT N/A
- 52 Week Low
- SWVL $2.40
- VTVT $12.62
- 52 Week High
- SWVL $7.50
- VTVT $26.99
- Technical
- Relative Strength Index (RSI)
- SWVL 36.87
- VTVT 69.51
- Support Level
- SWVL $3.36
- VTVT $15.79
- Resistance Level
- SWVL $3.75
- VTVT $19.26
- Average True Range (ATR)
- SWVL 0.30
- VTVT 0.54
- MACD
- SWVL -0.05
- VTVT 0.42
- Stochastic Oscillator
- SWVL 24.53
- VTVT 84.71
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About VTVT vTv Therapeutics Inc.
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.